Beigene's tislelizumab beats Nexavar in HCC

9 August 2022

Chinese biotech BeiGene (Nasdaq: BGNE) has announced that the global Phase III RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior overall survival (OS) versus sorafenib as a first-line treatment in adults with unresectable hepatocellular carcinoma (HCC).

Sorafenib, which was co-developed and co-marketed by Bayer (BAYN: DE) and Onyx Pharmaceuticals as Nexavar, is a kinase inhibitor that has been on the market in the USA and Europe for HCC, the most common form of liver cancer, for nearly 15 years.

There were no alarms on the safety front in the RATIONALE trial, which involved more than 600 patients in the USA, Europe, and Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK